Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Jan 5;9(15):12351-12364.
doi: 10.18632/oncotarget.24033. eCollection 2018 Feb 23.

Genetic polymorphisms of IL-6 promoter in cancer susceptibility and prognosis: a meta-analysis

Xingchun Peng  1 , Jun Shi  2 , Wanqun Sun  3 , Xuzhi Ruan  1 , Yang Guo  1 , Lunhua Zhao  1 , Jue Wang  1 , Bin Li  3
Affiliations

Genetic polymorphisms of IL-6 promoter in cancer susceptibility and prognosis: a meta-analysis

Xingchun Peng et al. Oncotarget. .

Abstract

IL-6 is critical for tumorigenesis. However, previous studies on the association of IL-6 promoter polymorphisms with predisposition to different cancer types are somewhat contradictory. Therefore, we performed this meta-analysis regarding the relationship between IL-6 promoter single nucleotide polymorphisms and cancer susceptibility and prognosis. Up to April 2017, 97 original publications were identified covering three IL-6 promoter SNPs. Our results showed statistically significant association between IL-6 promoter and cancer risk and prognosis. Subgroup analysis indicated that rs1800795 was significantly associated with increased risk of cervical cancer, colorectal cancer, breast cancer, prostate cancer, lung cancer, glioma, non-Hodgkin's lymphoma and Hodgkin's lymphoma but not gastric cancer and multiple myeloma. Furthermore, rs1800796 was significantly associated with increased risk of lung cancer, prostate cancer and colorectal cancer but not gastric cancer. Additionally, rs1800797 was significantly association with breast cancer, non-Hodgkin's lymphoma, B-cell lymphoma and diffuse large B-cell lymphoma but not gastric cancer. Simultaneously, rs1800795 and rs1800796 were associated with a significantly higher risk of cancer in Asia and Caucasian, rs1800797 was associated with a significantly risk of cancer in Caucasian but not in Asia. Furthermore, IL-6 promoter polymorphisms were significantly associated with the prognosis of cancer. Considering these promising results, IL-6 promoter including rs1800795, rs1800796 and rs1800797 may be a tumor marker for cancer therapy.

Keywords: IL-6; cancer; case-control studies; meta-analysis.

PubMed Disclaimer

Conflict of interest statement

CONFLICTS OF INTERESTS No conflicts of financail interests is stated by authors.

Figures

Figure 1
Figure 1. Flow diagram of the study selection process
See this image and copyright information in PMC

References

    1. Kishimoto T. Interleukin-6: from basic science to medicine--40 years in immunology. Annu Rev Immunol. 2005;23:1–21. - PubMed
    1. Tchirkov A, Khalil T, Chautard E, Mokhtari K, Veronese L, Irthum B, Vago P, Kemeny JL, Verrelle P. Interleukin-6 gene amplification and shortened survival in glioblastoma patients. Br J Cancer. 2007;96:474–6. - PMC - PubMed
    1. Blay JY, Farcet JP, Lavaud A, Radoux D, Chouaib S. Serum concentrations of cytokines in patients with Hodgkin’s disease. Eur J Cancer. 1994;30A:321–4. - PubMed
    1. Winther KV, Jess T, Langholz E, Munkholm P, Binder V. Survival and cause-specific mortality in ulcerative colitis: follow-up of a population-based cohort in Copenhagen County. Gastroenterology. 2003;125:1576–82. - PubMed
    1. Terry CF, Loukaci V, Green FR. Cooperative influence of genetic polymorphisms on interleukin 6 transcriptional regulation. J Biol Chem. 2000;275:18138–44. - PubMed

LinkOut - more resources